Growth and survival of B-chronic lymphocytic leukaemia cells
- PMID: 9789213
- DOI: 10.1007/BF02989583
Growth and survival of B-chronic lymphocytic leukaemia cells
Abstract
Although chronic lymphocytic leukaemia of B cell type (B-CLL) is the most common form of leukaemia in the Western world, several questions about the biology of B-CLL remain to be clarified. To obtain a conceptual model for B-CLL, defined as a relentless accumulation of resting B-CLL cells, it is particularly relevant to ask which cell type is the normal counterpart of B-CLL; what is the site of proliferation; which signals are involved in the recruitment and induction of proliferation and which signals contribute to the survival of the B-CLL cells? The significance of the studies on B-CLL cells in vitro for the interpretation of the in vivo situation may be questioned since they oversimplify the multiple and complex cellular interactions that occur in vivo. However, the in vitro studies have been instrumental in elucidating signals that may regulate growth, differentiation and survival of B-CLL cells. This knowledge, herein reviewed, can be used to put forward a hypothesis on B-CLL cell regulation in vivo.
Similar articles
-
The Important Role of STAT3 in Chronic Lymphocytic Leukaemia Biology.Klin Onkol. 2020 Winter;33(1):32-38. doi: 10.14735/amko202032. Klin Onkol. 2020. PMID: 32075387 Review. English.
-
MEK1/2 inhibition by binimetinib is effective as a single agent and potentiates the actions of Venetoclax and ABT-737 under conditions that mimic the chronic lymphocytic leukaemia (CLL) tumour microenvironment.Br J Haematol. 2018 Aug;182(3):360-372. doi: 10.1111/bjh.15282. Epub 2018 May 16. Br J Haematol. 2018. PMID: 29767411
-
Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.Drugs. 2003;63(8):803-43. doi: 10.2165/00003495-200363080-00005. Drugs. 2003. PMID: 12662126 Review.
-
Apoptosis in B-chronic lymphocytic leukaemia.Med Oncol. 1998 Dec;15(4):234-40. doi: 10.1007/BF02787206. Med Oncol. 1998. PMID: 9951686 Review.
-
CCL2 and CXCL2 enhance survival of primary chronic lymphocytic leukemia cells in vitro.Leuk Lymphoma. 2012 Oct;53(10):1988-98. doi: 10.3109/10428194.2012.672735. Epub 2012 Apr 19. Leuk Lymphoma. 2012. PMID: 22397722
Cited by
-
Cytokine expression in B-CLL in relation to disease progression and in vitro activation.Med Oncol. 1999 Dec;16(4):289-95. doi: 10.1007/BF02785875. Med Oncol. 1999. PMID: 10618692